Clinical Trials Logo
  1. Home
  2. Myotonic Dystrophy
  3. NCT00167609

Efficacy and Safety of DHEA for Myotonic Dystrophy

Myotonic Dystrophy Clinical Trial

Official title:
Phase 3 Study of Oral Dehydroepiandrosterone (DHEA) in Adults With Myotonic Dystrophy

Clinical Trial Summary

To test the efficacy and safety of two doses of dehydroepiandrosterone (DHEA) in adults with myotonic dystrophy

Clinical Trial Description

Myotonic dystrophy is an inherited disorder that affects 1 per 8000 adults. The disease is characterize by muscular dystrophy, myotonia, cardiac disorders, cognitive function impairment, hypersomnia, hair loss, endocrine disorders. Recent small studies suggested that DHEA treatment may improve muscle strength in adults with myotonic dystrophy. Thus, the current study aims at investigating the safety and efficacy of a prolonged treatment with DHEA in adults with myotonic dystrophy. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00167609
Study type Interventional
Source University of Versailles
Contact
Status Completed
Phase Phase 2/Phase 3
Start date November 2004
Completion date December 2006
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04624750 - Open Label Study in Adolescents and Children With Myotonic Disorders Phase 3
Recruiting NCT00082108 - Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry
Recruiting NCT05890833 - The Risk of Falls Index for Patients With Neuromuscular Disorders
Completed NCT05027269 - Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients Phase 1/Phase 2
Completed NCT00233519 - Effects of SomatoKine (Iplex)Recombinant Human Insulin-like Growth Factor-1/Recombinant Human Insulin-like Growth Factor-binding Protein-3 (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1) Phase 1/Phase 2
Not yet recruiting NCT06411288 - Global Study of Del-desiran for the Treatment of DM1 Phase 3
Recruiting NCT04003363 - The United Kingdom National Registry for Myotonic Dystrophy
Completed NCT01136330 - DM1 Heart Registry - DM1 Respiratory Registry N/A
Completed NCT02375087 - Sleep Breathing Disorders, a Main Trigger for Cardiac ARythmias in Type I Myotonic Dystrophy ?
Completed NCT01406873 - Clinical Efficacy Trial of Mexiletine for Myotonic Dystrophy Type 1 Phase 2
Completed NCT03959189 - Safety, Tolerability and Pharmacokinetics of ERX-963 in Adults With Myotonic Dystrophy Type 1 Phase 1
Completed NCT01931644 - At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
Recruiting NCT00127582 - RAMYD Study - Evaluation of Arrhythmic Risk in Myotonic Dystrophy Phase 3
Recruiting NCT02398786 - Myotonic Dystrophy Family Registry
Recruiting NCT05019625 - Biomarker Development for Muscular Dystrophies
Recruiting NCT05020002 - Extracellular RNA Biomarkers of Myotonic Dystrophy
Active, not recruiting NCT04616807 - An Observational Study in Adult Patients With Non-dystrophic Myotonic Disorders
Active, not recruiting NCT05479981 - Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients Phase 2
Terminated NCT02315339 - European Home Mechanical Ventilation Registry
Not yet recruiting NCT06147414 - Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders